最新报道！名导郎昆执导史诗话剧《西去东来》，老艺术家齐聚致敬中华文化瑰宝

名导郎昆执导史诗话剧《西去东来》，老艺术家齐聚致敬中华文化瑰宝

北京 - 9月15日至17日，由著名导演郎昆执导的中国非遗主题史诗话剧《西去东来》在北京保利剧院精彩上演，该剧以“百年老字号”东来顺为背景，讲述了其120年的风雨历程和时代变迁，展现了中华饮食文化的传承与发展。该剧的演出不仅吸引了众多观众前来观看，更得到了众多老艺术家的鼎力支持和高度评价。

著名表演艺术家刘佩琦、李立群、濮存昕、宋丹丹、冯远等老艺术家齐聚北京保利剧院，观看了《西去东来》的演出。演出结束后，老艺术家们纷纷对该剧给予了高度评价。刘佩琦表示，该剧“立意新颖、剧情感人、制作精良”，是一部不可多得的优秀作品。李立群认为，该剧“不仅展现了中华饮食文化的博大精深，更弘扬了中华民族的传统美德”。濮存昕则表示，该剧“给观众带来了美的享受和精神的启迪”。

话剧《西去东来》由著名编剧王丽媛执笔，以东来顺为缩影，展现了中华饮食文化的传承与发展。该剧从清末民初的皇宫御膳，到民国时期的风云变幻，再到新中国成立后的沧桑巨变，全景式地展现了中华饮食文化的历史脉络。剧中不仅有精美的服饰道具和逼真的舞台场景，更有着扣人心弦的故事情节和生动的人物形象。

该剧的演出不仅得到了老艺术家的肯定，也受到了广大观众的喜爱。许多观众表示，该剧让他们“回味无穷、受益匪浅”。有观众表示，该剧“不仅是一部好看的话剧，更是一堂生动的历史课”。还有观众表示，该剧“让他们更加了解了中华饮食文化，更加热爱中华民族的传统文化”。

话剧《西去东来》的成功演出，是对我国民俗文化遗产的一次保护和弘扬，也是对中华优秀传统文化的传承和创新。该剧的演出不仅丰富了北京的文化生活，也为振兴中华优秀传统文化贡献了力量。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.